Glucosylsphingosine is a reliable response biomarker in Gaucher disease

Am J Hematol. 2018 Jun;93(6):E140-E142. doi: 10.1002/ajh.25074. Epub 2018 Mar 15.

Authors

David Arkadir¹, Tama Dinur², Shoshana Revel-Vilk², Michal Becker Cohen², Claudia Cozma³, Marina Hovakimyan³, Sabrina Eichler³, Arndt Rolfs^{3

4}, Ari Zimran²

Affiliations

¹ Hadassah Medical Center, Hebrew University, Jerusalem, Israel.
² Gaucher unit, Shaare Zedek Medical Center, Hebrew University, Jerusalem, Israel.
³ Centogene AG, Rare Disease Company, Rostock, Germany.
⁴ Albrecht-Kossel-Institute for Neuroregeneration, University of Rostock, Rostock, Germany.

PMID: 29473199
DOI: 10.1002/ajh.25074

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Drug Monitoring
Enzyme Replacement Therapy
Gaucher Disease / diagnosis*
Gaucher Disease / drug therapy
Humans
Psychosine / analogs & derivatives*
Psychosine / analysis
Psychosine / blood
Retrospective Studies

Substances

Biomarkers
Psychosine
sphingosyl beta-glucoside